$CLPT
ClearPoint Neuro, Inc.

2023 Q3 Form 10-Q Financial Statement

#000128555023000097 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $5.762M $5.950M $5.200M
YoY Change 11.97% 14.42% 52.36%
Cost Of Revenue $2.489M $2.824M $1.943M
YoY Change 73.57% 45.34% 70.59%
Gross Profit $3.273M $3.126M $3.257M
YoY Change -11.83% -4.02% 43.23%
Gross Profit Margin 56.8% 52.54% 62.63%
Selling, General & Admin $2.900M $3.178M $5.177M
YoY Change -42.62% -38.61% 44.93%
% of Gross Profit 88.6% 101.66% 158.95%
Research & Development $2.429M $3.605M $2.284M
YoY Change -0.98% 57.84% 8.3%
% of Gross Profit 74.21% 115.32% 70.13%
Depreciation & Amortization $150.0K $156.0K $101.0K
YoY Change 305.41% 54.46% 140.48%
% of Gross Profit 4.58% 4.99% 3.1%
Operating Expenses $5.329M $6.783M $7.461M
YoY Change -29.01% -9.09% 31.33%
Operating Profit -$4.897M -$7.131M -$4.204M
YoY Change 29.04% 69.62% 23.39%
Interest Expense $100.0K $81.00K -$91.00K
YoY Change 212.5% -189.01% -62.08%
% of Operating Profit
Other Income/Expense, Net -$12.00K -$2.000K -$8.000K
YoY Change -52.0% -75.0% -91.67%
Pretax Income -$4.810M -$7.052M -$4.303M
YoY Change 26.98% 63.89% 14.96%
Income Tax
% Of Pretax Income
Net Earnings -$4.809M -$7.052M -$4.303M
YoY Change 26.95% 63.89% 14.96%
Net Earnings / Revenue -83.46% -118.52% -82.75%
Basic Earnings Per Share -$0.20 -$0.29 -$0.18
Diluted Earnings Per Share -$0.20 -$0.29 -$179.4K
COMMON SHARES
Basic Shares Outstanding 24.64M shares 24.58M shares 23.72M shares
Diluted Shares Outstanding 24.63M shares 24.58M shares 23.99M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.34M $26.46M $45.14M
YoY Change -39.84% -41.37% -26.64%
Cash & Equivalents $24.30M $26.50M $23.52M
Short-Term Investments $0.00 $0.00 $21.61M
Other Short-Term Assets $1.560M $2.244M $1.517M
YoY Change -5.91% 47.92% 51.25%
Inventory $8.987M $9.204M $6.639M
Prepaid Expenses
Receivables $2.424M $2.799M $3.348M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $37.31M $40.71M $56.64M
YoY Change -30.67% -28.12% -17.32%
LONG-TERM ASSETS
Property, Plant & Equipment $1.355M $1.360M $2.681M
YoY Change -45.69% -49.27% -5.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $109.0K $156.0K $598.0K
YoY Change -81.17% -73.91% -10.75%
Total Long-Term Assets $6.527M $6.930M $3.599M
YoY Change 66.34% 92.55% -5.71%
TOTAL ASSETS
Total Short-Term Assets $37.31M $40.71M $56.64M
Total Long-Term Assets $6.527M $6.930M $3.599M
Total Assets $43.84M $47.64M $60.24M
YoY Change -24.08% -20.91% -16.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $789.0K $1.273M $1.592M
YoY Change -43.11% -20.04% 27.16%
Accrued Expenses $3.630M $4.205M $3.216M
YoY Change -8.63% 30.75% 16.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.589M $6.202M $5.483M
YoY Change -8.3% 13.11% 25.04%
LONG-TERM LIABILITIES
Long-Term Debt $9.940M $9.921M $9.865M
YoY Change 0.62% 0.57% -43.64%
Other Long-Term Liabilities $4.220M $4.108M $2.072M
YoY Change 123.75% 98.26% -16.15%
Total Long-Term Liabilities $14.16M $14.03M $11.94M
YoY Change 20.36% 17.53% -40.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.589M $6.202M $5.483M
Total Long-Term Liabilities $14.16M $14.03M $11.94M
Total Liabilities $19.74M $20.23M $17.42M
YoY Change 10.54% 16.14% -28.49%
SHAREHOLDERS EQUITY
Retained Earnings -$167.8M -$163.0M
YoY Change
Common Stock $191.9M $190.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.09M $27.41M $42.82M
YoY Change
Total Liabilities & Shareholders Equity $43.84M $47.64M $60.24M
YoY Change -24.08% -20.91% -16.71%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$4.809M -$7.052M -$4.303M
YoY Change 26.95% 63.89% 14.96%
Depreciation, Depletion And Amortization $150.0K $156.0K $101.0K
YoY Change 305.41% 54.46% 140.48%
Cash From Operating Activities -$1.790M -$5.075M -$4.981M
YoY Change -53.53% 1.89% 33.93%
INVESTING ACTIVITIES
Capital Expenditures $230.0K $490.0K -$76.00K
YoY Change -136.45% -744.74% -317.14%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00M -$21.59M
YoY Change -146.32%
Cash From Investing Activities -$230.0K $9.510M -$21.67M
YoY Change -63.55% -143.89% -62002.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -90.00K 237.0K 513.0K
YoY Change -72.64% -53.8% 46.99%
NET CHANGE
Cash From Operating Activities -1.790M -5.075M -4.981M
Cash From Investing Activities -230.0K 9.510M -21.67M
Cash From Financing Activities -90.00K 237.0K 513.0K
Net Change In Cash -2.110M 4.672M -26.13M
YoY Change -56.15% -117.88% 683.63%
FREE CASH FLOW
Cash From Operating Activities -$1.790M -$5.075M -$4.981M
Capital Expenditures $230.0K $490.0K -$76.00K
Free Cash Flow -$2.020M -$5.565M -$4.905M
YoY Change -37.29% 13.46% 30.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23985577 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23985577 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24583439 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24583439 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48787000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
899000 usd
CY2022Q1 clpt Warrant And Option Exercises Cash And Cashless
WarrantAndOptionExercisesCashAndCashless
3000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3959000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
45730000 usd
CY2022Q2 clpt Warrant And Option Exercises Cash And Cashless
WarrantAndOptionExercisesCashAndCashless
253000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
260000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4303000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
42820000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8262000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
454000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-10000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
285000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
187000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2952000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1779000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
28000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
27000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
325000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
267000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
126000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
23000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
588000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1001000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-94000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1786000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
438000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1010000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
25000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-30000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-282000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
679000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-293000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-261000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-480000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
134000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10755000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9250000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
461000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
145000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
167000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
116000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
21590000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
10000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9372000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21851000 usd
clpt Proceeds From Stock Option And Warrant Exercises
ProceedsFromStockOptionAndWarrantExercises
0 usd
clpt Proceeds From Stock Option And Warrant Exercises
ProceedsFromStockOptionAndWarrantExercises
256000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
82000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
314000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
260000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
232000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
516000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1151000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30585000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27615000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54109000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26464000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23524000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
369000 usd
us-gaap Interest Paid Net
InterestPaidNet
207000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
200000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
100000 usd
clpt Net Transfers Of Reusable Components From Loaned Systems
NetTransfersOfReusableComponentsFromLoanedSystems
100000 usd
clpt Net Transfers Of Reusable Components From Loaned Systems
NetTransfersOfReusableComponentsFromLoanedSystems
100000 usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2500000 usd
CY2023Q2 clpt Number Of Companies
NumberOfCompanies
50 company
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10800000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2022 audited consolidated financial statements, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth therein. These condensed consolidated financial statements have been prepared in accordance with SEC rules for interim financial information, and, therefore, omit certain information and footnote disclosures necessary to present such statements in accordance with GAAP. The preparation of these condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s 2022 Form 10-K. The accompanying condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all information and footnotes required by GAAP for a complete set of financial statements. The results of operations for the three and six months ended June 30, 2023, may not be indicative of the results to be expected for the entire year or any future periods.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments. The Company classifies the U.S. government debt securities as held-to-maturity in accordance with ASC 320, "Investments - Debt and Equity Securities." Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity and are recorded at amortized cost on the accompanying condensed consolidated balance sheet, adjusted for the accretion of discounts using the effective interest method.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At June 30, 2023, the Company had approximately $1.6 million in bank balances that were in excess of the insured limits. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023, there were three customers whose accounts receivable balances represented 24%, 12%, and 11% of accounts receivable at that date. At December 31, 2022, one customer accounted for 19% of accounts receivable at that date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One pharmaceutical customer, a related party who is a stockholder, a noteholder, and whose Chief Executive Officer is a representative on the Company's Board of Directors (see Note 6), for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 12% and 14% of total sales in the three-month periods ended June 30, 2023 and 2022, respectively, and 13% and 16% of total sales in the six-month periods ended June 30, 2023 and 2022, respectively. There were two additional customers who comprised 14% and 13% of the total sales in the three-month period ended June 30, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to granting credit to a customer, the Company generally performs credit evaluations of the customers’ financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at June 30, 2023, and December 31, 2022, was $0.6 million and $0.1 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; dependence on third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.</span></div>
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1600000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
600000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
100000 usd
CY2023Q2 clpt Inventory Software Licenses
InventorySoftwareLicenses
210000 usd
CY2022Q4 clpt Inventory Software Licenses
InventorySoftwareLicenses
210000 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated statement of operations for the three and six months ended June 30, 2023 classifies share-based compensation in the same income statement line items as the cash compensation paid to recipient employees, rather than in general and administrative expense, as had been the practice in previous years. The accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2022 have been conformed to the 2023 presentation.</span></div>
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5950000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5200000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11383000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10231000 usd
CY2022Q4 clpt Deferred Contract Costs Current
DeferredContractCostsCurrent
300000 usd
CY2022Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
500000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
900000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.73
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26500000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27600000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
9900000 usd
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7315000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6513000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1679000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2580000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
9204000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9303000 usd
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
407000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
450000 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
9611000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
9753000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10000000 usd
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
79000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
9921000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
200000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
100000 usd
us-gaap Lease Cost
LeaseCost
300000 usd
us-gaap Lease Cost
LeaseCost
300000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1645000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
880000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2952000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1779000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1645000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
880000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1779000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1398286 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
111107 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.10
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
3437 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
39.67
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1505956 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y11M4D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4097000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1198832 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.18
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M15D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3951000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1505956 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y11M4D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4097000 usd
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001285550-23-000097-index-headers.html Edgar Link pending
0001285550-23-000097-index.html Edgar Link pending
0001285550-23-000097.txt Edgar Link pending
0001285550-23-000097-xbrl.zip Edgar Link pending
clpt-20230630.htm Edgar Link pending
clpt-20230630.xsd Edgar Link pending
clpt-20230630xex311.htm Edgar Link pending
clpt-20230630xex312.htm Edgar Link pending
clpt-20230630xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
clpt-20230630_def.xml Edgar Link unprocessable
clpt-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
clpt-20230630_htm.xml Edgar Link completed
clpt-20230630_lab.xml Edgar Link unprocessable
clpt-20230630_cal.xml Edgar Link unprocessable